Here is the design of a clinical trial:

Official Title: EfiKroniK Research Program: Effectiveness of Physical Exercise for People With Chronic Pathologies. Hybrid, Clinical and Implementation Randomized Trial

Included conditions:
- Neoplasms
- Schizophrenia
- COPD
- Physical Activity
- Quality of Life
- Primary Care

Study Armgroups:
- {'label': 'Control group', 'type': 'OTHER', 'description': 'Personalized program (PVS), of proven effectiveness for the promotion of physical activity, diet and smoking cessation.', 'interventionNames': ['Other: Personalized Supervised physical activity']}
- {'label': 'Supervision group', 'type': 'OTHER', 'description': 'Personalized Supervised physical activity: personalized exercise program for patients, supervised during 3 months by nursing in primary and autonomous care afterwards, with support from community resources', 'interventionNames': ['Other: Personalized Supervised physical activity']}

Interventions:
- {'type': 'OTHER', 'name': 'Personalized Supervised physical activity', 'description': 'personalized exercise program for patients, supervised during 3 months by nursing in primary and autonomous care afterwards, with support from community resources', 'armGroupLabels': ['Control group', 'Supervision group']}

Primary Outcomes:
- {'measure': 'Change in Functional capacity (6 minute walking test)', 'description': 'The Test of the 6-minute applies to assess functional capacity, as well as a predictor of morbidity and mortality in people with different pathologies. Most of the daily activities that the patients with these pathologies are performed at submaximal exercise intensity, similar to this test is performed. In addition, as a method of controlling the intensity. Measurements: baseline, at the end of the exercise program, at 6 and 12 months', 'timeFrame': 'One year follow up'}

Please estimate the sample size based on the assumption: 
Significance level (alpha) = 0.05, power = 90% for most outcomes, 80% power for physical and emotional roles in SF-36 questionnaire, standard deviation of 40s, intra-patient correlation of 0.6, and a 30% loss to follow-up rate.
Sample size
        We expect to recruit a total of 370 patients over 2âyears; with a loss to follow-up (including deaths) of 30%, this would provide the study with a power of over 90% to detect differences between the two comparison groups in the primary outcome variable (400-m walk completion time) of at least 6âs after 3âmonths, 12âs after 6âmonths and 24âs after 12âmonths of follow-up as significant (alphaâ=â0.05), assuming a linear increase in the impact of the exercise over time, a standard deviation of 40âs and intra-patient correlation of 0.6. These differences are less than those found in previous studies.
        Regarding the quality of life outcome variable, we would have a power of 90% to detect differences between the two groups of 2.5 points at 3âmonths, 5 points at 6âmonths and 10 points at 12âmonths as significant (alphaâ=â0.05), for all the dimensions of the SF-36 questionnaire, except for physical and emotional roles (80% power) [40].